Group 1 - The core viewpoint of the article highlights the financial performance and market position of BGM, indicating a stock price increase and a notable market capitalization [1] - As of March 31, 2025, BGM reported total revenue of $14.31 million, reflecting a year-on-year growth of 13.92% [1] - The company experienced a net loss attributable to shareholders of $0.8612 million, which represents a significant year-on-year decrease of 307.79% [1] Group 2 - BGM, formerly known as Qilian International Holdings Group, is headquartered in Chengdu, China, and focuses on innovative sectors such as biopharmaceuticals, bio-extraction, and healthcare [1] - The company's product range includes tetracycline raw materials, licorice preparations, and crude heparin sodium, which are essential for both human pharmaceuticals and agricultural applications [1] - Tetracycline raw materials support the production of human antibiotics and ensure safety in poultry and aquaculture, while crude heparin sodium is processed into refined heparin sodium and injectable heparin sodium solutions, serving as a primary anticoagulant [1]
博美集团上涨3.05%，报9.594美元/股，总市值17.65亿美元